Publicacións (9) Publicacións de Luis Margusino Framiñán

filter_list Immunology

2023

  1. Lipid profile changes associated with antiretroviral therapies in a real-world cohort

    Farmacia Hospitalaria, Vol. 47, Núm. 5, pp. 210-217

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

2019

  1. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  2. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

2017

  1. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

2007

  1. Influencia de las pruebas de resistencias a antirretrovirales sobre la efectividad del tratamiento en pacientes con infección por VIH y fracaso virológico

    Farmacia Hospitalaria, Vol. 31, Núm. 1, pp. 23-29

2004

  1. Análisis del tratamiento antirretroviral inicial en pacientes VIH

    Farmacia Hospitalaria, Vol. 28, Núm. 6 SUPPL. 1, pp. 40-47

  2. Cambio del tratamiento antirretroviral en el paciente VIH

    Farmacia Hospitalaria, Vol. 28, Núm. 6 SUPPL. 1, pp. 48-54